Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

Claim 1 (previously presented): A quinazoline derivative of formula I:

wherein:

m is 0, 1 or 2:

each ${\bf R}^1$, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy,

(3-7C)cvcloalkvl-oxy and (3-7C)cvcloalkvl-(1-6C)alkoxy,

wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy:

R² is hydrogen or (1-4C)alkyl;

n is 0, 1, 2, 3 or 4;

each R³, which may be the same or different, is selected from cyano, halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

$$\begin{split} \mathbf{X}^{1} \text{ is selected from O, S, SO, SO}_{2}, N(R^{7}), CH(OR^{7}), CON(R^{7}), N(R^{7})CO, SO_{2}N(R^{7}), N(R^{7})SO_{2}, \\ OC(R^{7})_{2}, C(R^{7})_{2}O, SC(R^{7})_{2}, C(R^{7})_{2}S, CO, C(R^{7})_{2}N(R^{7}) \text{ and } N(R^{7})C(R^{7})_{2}; \end{split}$$

each R⁷, which may be the same or different, is hydrogen or (1-6C)alkyl;

- Q1 is aryl, or heteroaryl,
- wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy, (1-4C)alkyl and (1-4C)alkoxy;
- wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];
- R⁴, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or
 - R^4 and R^{4a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or
 - R^5 and R^{5a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring.
- wherein any CH₂ or CH₃ group within any of R⁴, R^{5a} and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];
- R⁶ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl,
- wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula: X³. R¹⁰:
- X3 is a direct bond or is selected from O, CO, SO2 and N(R11);
- ${f R}^{11}$ is hydrogen or (1-4C)alkyl;
- R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, <u>N</u>-(1-4C)alkylamino-(1-4C)alkyl and <u>N,N</u>-di-[(1-4C)alkyl]amino-(1-4C)alkyl,

- wherein any heterocyclyl group within an R^6 substituent optionally bears 1 or 2 oxo or thioxo substituents, and
- wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N.N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino), N-(1-6C)alkyl-(1-6C)

A is selected from hydrogen, a group of the formula Z-(CR¹²R¹³)_n- and R¹⁴;

p is 1, 2, 3, or 4;

- each R¹² and R¹³, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl.
 - or an R¹² and an R¹³ group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring,
- wherein any CH₂ or CH₃ group within any of R¹² and R¹³, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di[(1-6C)alkyl]amino;
- Z is selected from hydrogen, OR¹⁵, NR¹⁶R¹⁷, (1-6C)alkylsulfonyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;
- each of \mathbf{R}^{15} , \mathbf{R}^{16} and \mathbf{R}^{17} , which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl and (1-6C)alkoxycarbonyl, or Z is a group of the formula: $Q^2 X^4$;

X4 is selected from O, N(R18), SO2 and SO2N(R18);

N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

R¹⁸ is hydrogen or (1-6C)alkyl;

Q² is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl;

- R14 is selected from hydrogen, OR19 and NR16R17;
- R¹⁹ is selected from (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, wherein R¹⁶ and R¹⁷ are as defined above,
 - or R¹⁴ is a group of the formula: O³-X⁵-:
- X5 is selected from O and N(R20);
- R²⁰ is hydrogen or (1-6C)alkyl;
- $$\begin{split} &Q^3 \text{ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, or R^{14} is Q^4; \end{split}$$
- Q⁴ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl.
- wherein adjacent carbon atoms in any (2-6C)alkylene chain within a Z or R¹⁴ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R²¹), CO, -C=C- and -C≡C-:
- R²¹ is hydrogen or (1-6C)alkyl.
- wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula: X^6 . R²².
- X⁶ is a direct bond or is selected from O, CO, SO₂ and N(R²³);
- R²³ is hydrogen or (1-4C)alkyl;
- R²² is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, <u>N</u>-(1-4C)alkylamino-(1-4C)alkyl and N.N-di-[(1-4C)alkyl]amino-(1-4C)alkyl.
- wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears 1 or 2 oxo or thioxo substituents, and

wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfinyl, (1-6C)alkylsulfamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, N-(1-6C)alkylsulfamoyl, NN-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkylsulfamoyl, NN-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkyl-(1-6C)alkanosulfonylamino; or a pharmaceutically acceptable salt thereof.

Claim 2 (previously presented): The quinazoline derivative according to claim 1, wherein: **m** is 0, 1 or 2;

each R¹, which may be the same or different, is selected from hydroxy, (1-6C)alkoxy, (3-7C)cycloalkyl-oxy and (3-7C)cycloalkyl-(1-6C)alkoxy,

wherein any CH₂ or CH₃ group within a R¹ substituent optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy,

R² is hydrogen or (1-4C)alkyl;

n is 0, 1, 2, 3 or 4:

each R³, which may be the same or different, is selected from halogeno, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

$$\begin{split} X^1 \text{ is selected from O, S, SO, SO}_2, N(R^7), CH(OR^7), CON(R^7), N(R^7)CO, SO}_2N(R^7), N(R^7)SO}_2, \\ OC(R^7)_2, C(R^7)_2O, SC(R^7)_2, C(R^7)_2S, CO, C(R^7)_2N(R^7) \text{ and } N(R^7)C(R^7)_2; \end{split}$$

each \mathbb{R}^7 , which may be the same or different, is hydrogen or (1-6C)alkyl;

Q1 is aryl, or heteroaryl,

wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy, (1-4C)alkyl and (1-4C)alkoxy,

- wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino];
- R⁴, R^{5a}, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, or
 - R⁴ and R^{4a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring, or
 - R⁵ and R^{5a} together with the carbon atom to which they are attached form a (3-7C)cycloalkyl ring,
- wherein any CH₂ or CH₃ group within any of R⁴, R^{5a} and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino];
- R⁶ is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl, and
- wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula: -X³-R¹⁰:
- X³ is a direct bond or is selected from O, CO, SO₂ and N(R¹¹);
- R¹¹ is hydrogen or (1-4C)alkyl, and R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl, and N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl,
- wherein any heterocyclyl group within an R⁶ substituent optionally bears 1 or 2 oxo or thioxo substituents, and
- wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or

```
(1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio.
```

(1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino,

N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl,

(2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,

N-(1-6C)alkylsulfamoyl, N.N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

A is selected from hydrogen, a group of the formula Z-(CR12R13)p- and R14;

p is 1, 2, 3, or 4,

each R¹² and R¹³, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or an R¹² and an R¹³ group attached to the same carbon atom form a (3-7C)cycloalkyl or (3-7C)cycloalkenyl ring,

wherein any CH₂ or CH₃ group within any of R¹² and R¹³, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, (1-6C)alkyl, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di[(1-6C)alkyl]amino;

Z is selected from hydrogen, OR¹⁵, NR¹⁶R¹⁷, (1-6C)alkylsulfonyl, (1-6C)alkanesulfonylamino and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino;

each of ${\bf R^{15}}$, ${\bf R^{16}}$ and ${\bf R^{17}}$, which may be the same or different, is selected from hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl,

or Z is a group of the formula: Q2-X4-;

X4 is selected from O, N(R18), SO2 and SO2N(R18);

R¹⁸ is hydrogen or (1-6C)alkyl;

Q² is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl;

R¹⁴ is selected from hydrogen, OR¹⁹ and NR¹⁶R¹⁷;

R¹⁹ is selected from (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl, and wherein R¹⁶ and R¹⁷ are as defined above.

or R¹⁴ is a group of the formula: Q³-X⁵-;

- X⁵ is selected from O and N(R²⁰), wherein R²⁰ is hydrogen or (1-6C)alkyl;
- Q³ is (3-7C)cycloalkyl, (3-7C)cycloalkyl-(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl-(1-6C)alkyl, heterocyclyl and heterocyclyl-(1-6C)alkyl,
 - or R14 is Q4 wherein Q4 is (3-7C)cycloalkyl, (3-7C)cycloalkenyl or heterocyclyl,
- wherein adjacent carbon atoms in any (2-6C)alkylene chain within a Z or R¹⁴ substituent are optionally separated by the insertion into the chain of a group selected from O, S, SO, SO₂, N(R²¹), CO, -C=C- and -C≡C-;
- R21 is hydrogen or (1-6C)alkyl,
- wherein any heterocyclyl group within a Z or R ¹⁴ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, formyl, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula: $-X^6$. R²².
- X⁶ is a direct bond or is selected from O, CO, SO₂ and N(R²³);
- R²³ is hydrogen or (1-4C)alkyl;
- R²² is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, <u>N</u>-(1-4C)alkylamino-(1-4C)alkyl and N,N-di-[(1-4C)alkyl]amino-(1-4C)alkyl,
- wherein any heterocyclyl group within a Z or R¹⁴ substituent optionally bears 1 or 2 oxo or thioxo substituents, and
- wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, carboxy, carbamoyl, sulfamoyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, N-(1-6C)alkylcarbamoyl, N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino,

 \underline{N} -(1-6C)alkylsulfamoyl, \underline{N} . \underline{N} -di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino and \underline{N} -(1-6C)alkyl-(1-6C)alkanesulfonylamino;

or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented): The quinazoline derivative according to claim 1, wherein R⁴, R⁴a, R⁵ and R^{5a}, which may be the same or different, are selected from hydrogen and (1-6C)alkyl, and wherein any CH₂ or CH₃ group within any of R⁴, R^{5a}, R⁵ and R^{5a} optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy, cyano, (1-6C)alkoxy, amino, (2-6C)alkanoyl, (1-6C)alkylamino and di-[(1-6C)alkylamino].

Claim 4 (previously presented): The quinazoline derivative according to claim 1, wherein m is 0

Claim 5 (previously presented): The quinazoline derivative according to claim 1, wherein \mathbb{R}^2 is hydrogen.

Claim 6 (previously presented): The quinazoline derivative according to claim 1, wherein n is 0, 1 or 2 and, when present, at least one R³ is in a meta-position (3-position) relative to the nitrogen of the anilino group in formula I.

Claim 7 (previously presented): The quinazoline derivative according to claim 1, wherein n is 1 and R³ is selected from halogeno and (1-4C)alkyl.

Claim 8 (previously presented): The quinazoline derivative according to claim 7, wherein R³ is chloro

Claim 9 (previously presented): The quinazoline derivative according to claim 7, wherein \mathbb{R}^3 is methyl.

Claim 10 (previously presented): The quinazoline derivative according to claim 1, wherein X^1 is selected from O, S, $OC(R^7)_2$, $SC(R^7)_2$, SO, SO_2 , $N(R^7)$, CO and $N(R^7)C(R^7)_2$ wherein each R^7 , which may be the same or different, is selected from hydrogen or (1-6C)alkyl.

Claim 11 (previously presented): The quinazoline derivative according to claim 1, wherein X^1 is selected from O, S and $OC(R^7)_2$ wherein each R^7 is, independently, hydrogen or (1-4C)alkyl.

Claim 12 (previously presented): The quinazoline derivative according to claim 1, wherein X^1 is OCH₂.

Claim 13 (previously presented): The quinazoline derivative according to claim 1, wherein

Q¹ is selected from phenyl and a 5- or 6-membered monocyclic heteroaryl ring, which ring contains 1, 2 or 3 heteroatoms independently selected from oxygen, nitrogen and sulfur, and wherein Q¹ optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy, (1-4C)alkyl and (1-4C)alkoxy,

wherein any CH₂ or CH₃ group within -X¹-Q¹ optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkylamino].

Claim 14 (previously presented): The quinazoline derivative according to claim 1, wherein Q¹ is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl.

Claim 15 (previously presented): The quinazoline derivative according to claim 1, wherein

R⁶ is selected from hydrogen, (1-3C)alkyl, (2-3C)alkenyl, (2-3C)alkynyl, (3-5C)cycloalkyl, (3-5C)cycloalkyl-(1-3C)alkyl, heterocyclyl and heterocyclyl-(1-3C)alkyl,

wherein any heterocyclyl group within an R⁶ substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, trifluoromethyl, cyano, nitro, hydroxy, amino, mercapto, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (2-6C)alkanoyl, (2-6C)alkanoyloxy and from a group of the formula: - x³- R¹⁰.

X3 is a direct bond or is selected from O and N(R11):

R11 is hydrogen or (1-4C)alkyl;

R¹⁰ is halogeno-(1-4C)alkyl, hydroxy-(1-4C)alkyl, (1-4C)alkoxy-(1-4C)alkyl, cyano-(1-4C)alkyl, amino-(1-4C)alkyl, N-(1-4C)alkylamino-(1-4C)alkyl and N-N-di-[(1-4C)alkyl]amino-(1-4C)alkyl,

wherein any heterocyclyl group within an R⁶ substituent optionally bears 1 or 2 oxo substituents; and wherein any CH₂ or CH₃ group within a R⁶ substituent, other than a CH₂ group within a heterocyclyl group, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 16 (previously presented): The quinazoline derivative according to claim 15, wherein R^6 is (1-3C)alkyl, and wherein any CH_2 or CH_3 group within a R^6 substituent, other than a CH_2 group within a heterocyclyl group, optionally bears on each said CH_2 or CH_3 group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, amino, (1-6C)alkylamino and di-[(1-6C)alkyl]amino.

Claim 17 (previously presented): The quinazoline derivative according to claim 1, wherein

A is selected from a group of the formula Z-(CR¹²R¹³)_p- and R¹⁴;

p is 1, 2 or 3;

- each R^{12} and R^{13} , which may be the same or different, is selected from hydrogen and (1-6C)alkyl,
- wherein any CH₂ or CH₃ group within any of R¹² and R¹³ optionally bears on each said CH₂ or CH₃ group one or more halogeno substituents or a substituent selected from hydroxy and (1-6C)alkoxy;
- Z is selected from hydrogen, OR15, NR16R17 and (1-6C)alkylsulfonyl;
- each of R¹⁵, R¹⁶ and R¹⁷, which may be the same or different, is selected from hydrogen, (1-6C)alkyl and (1-6C)alkoxycarbonyl;
- R14 is selected from OR19 and NR16R17;
- R¹⁹ is selected from (1-6C)alkyl and wherein R¹⁶ and R¹⁷ are as defined above, or R¹⁴ is O⁴;
- Q4 is (3-7C)cycloalkyl, heterocyclyl or heterocyclyl-(1-6C)alkyl,
- wherein any heterocyclyl group within a Z or R^{14} substituent optionally bears one or more substituents, which may be the same or different, selected from halogeno, hydroxy,
 - (1-6C)alkyl and (1-6C)alkoxy, and
- wherein any CH₂ or CH₃ group within a Z or R¹⁴ group, other than a CH₂ group within a heterocyclyl ring, optionally bears on each said CH₂ or CH₃ group one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy and (1-6C)alkoxy.

Claim 18 (previously presented): The quinazoline derivative selected from the following:

- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-methoxy-N-methylacetamide:
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-(dimethylamino)-N-methylacetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxy-N-methylacetamide);

- 2-hydroxy-N-methyl-N-{2-[(4-{3-methyl-4-(1,3-thiazol-4-ylmethoxy)anilino} quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-N-methyl-N-(2-{[4-(3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]anilino)quinazolin-5-ylloxy}ethyl)acetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-methoxyacetamide;
- N-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-2hydroxy-N-methylacetamide;
- N-((2R)-2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy} propyl)-2-hydroxy-N-methylacetamide;
- N-(2-{[4-(3-chloro-4-[(6-methylpyridin-2-yl)methoxy]anilino)quinazolin-5-yl]oxy}ethyl)-N-methylacetamide;
- N-(2-{[4-(3-chloro-4-[(2-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-N-methylacetamide;
- N-(2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-N-methylacetamide;
- N-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-N-methylacetamide;
- N-{2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-N-methylacetamide:
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2hydroxyacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-N-methylacetamide:
- 2-hydroxy-N-methyl-N-{2-[(4-{3-methyl-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxylethyl}acetamide;

- N-{(1R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]-1methylethyl}acetamide;
- N-{(1R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxyacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-N-methylacetamide;
- N-(2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy}ethyl)-2-hydroxy-N-methylacetamide;
- N-{2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-N-methylacetamide;
- N-{2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}-2-hydroxy-N-methylacetamide;
- N-{2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]ethyl}acetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy[propyl]acetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2hydroxy-N-methylacetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyrazin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2-hvdroxy-N-methylacetamide;
- N-((2R)-2-{[4-(3-chloro-4-[(3-fluorobenzyl)oxy]anilino)quinazolin-5-yl]oxy} propyl)-2-hydroxy-N-methylacetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(1,3-thiazol-4-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-2hvdroxy-N-methylacetamide;
- N-{(2R)-2-[(4-{3-chloro-4-(pyridin-2-ylmethoxy)anilino}quinazolin-5-yl)oxy]propyl}-N-methylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-ethylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-ethyl-2-hydroxyacetamide;

- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-Npropylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-propylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-isopropylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hvdroxy-N-isopropylacetamide;
- N-allyl-N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;
- N-allyl-N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-hvdroxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-cyclopropylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-cyclopropyl-2-hydroxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(cyclopropylmethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(cvclopropylmethyl)-2-hydroxyacetamide:
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-cvclobutvlacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-cyclobutyl-2-hydroxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(1-methylpiperidin-4-yl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(tetrahydro-2H-pyran-4-yl)acetamide;

- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-hydroxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-(2-hydroxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-(2-methoxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-(2-methoxyethyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-prop-2-yn-1-ylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-prop-2-yn-1-ylacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N-methylpropanamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-methyl-tetrahydrofuranyl-2-carboxamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N,1-dimethylprolinamide:
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxy-N,2-dimethylpropanamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-1hvdroxy-N-methylcyclopropanecarboxamide;
- N¹-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N¹,N²dimethylelycinamide:
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3hydroxy-N.2.2-trimethylpropanamide;

- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-3hvdroxy-N-methylpropanamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy[propyl}acetamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2hydroxvacetamide:
- N¹-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-N².N²-dimethylglycinamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-methoxyacetamide:
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-(methylsulfonyl)acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2hydroxyacetamide;
- N¹-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N²,N²dimethylglycinamide:
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2methoxyacetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2-(methylsulfonyl)acetamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-N-methylacetamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2hydroxy-N-methylacetamide;
- N¹-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}N¹.N².N²-trimethylglycinamide;
- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2-methoxy-N-methylacetamide;

- N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-N-methyl-2-(methylsulfonyl)acetamide;
- N-{(2R)-2-[(4-{[3-chloro-4-(pyrazin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-N-methylacetamide;
- N-{(2R)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxylpropyl}-N-methylacetamide;
- N-((2R)-2-{[4-({3-chloro-4-[(3-fluorobenzyl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-N-methylacetamide;
- N-((2R)-2-{[4-({3-chloro-4-[(2-fluorobenzyl)oxy]phenyl} amino)quinazolin-5-yl]oxy}propyl)-N-methylacetamide;
- N-{(1R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1methylethyl}-2-hydroxy-N-methylacetamide;
- N-{(1R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-N-methylacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-N-methylacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-N-methylacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-methoxy-N-methylacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxyacetamide;
- N-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}acetamide;
- N¹-{(1S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1methylethyl}-N²-N²-dimethylelycinamide;
- N^1 -{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}- N^2 - N^2 -dimethylglycinamide;

- (2S)-N-(2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yloxylpronyl}-2.4-dihydroxybutanamide;
- (2S)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy[propyl]-2,4-dihydroxybutanamide;
- (2R)-N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy[propyl]-2,4-dihydroxybutanamide;
- (2S)-N-{(2S)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5yl)oxylpropyl}-2,4-dihydroxybutanamide;
- (2S)-N-{(1R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{(1R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2S)-N-{2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-2,4-dihydroxybutanamide;
- (2R)-N-{(1R)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-methylethyl}-2.4-dihydroxybutanamide;
- (2S)-N-{(1R)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]-methylethyl}-2,4-dihydroxybutanamide;
- N-methyl-N-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;
- N-methyl-N-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxylethyl}acetamide;

- 2-hydroxy-N-methyl-N-{2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxy|ethyl}acetamide;
- 2-hydroxy-N-{2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy[ethyl}acetamide;
- 2-hydroxy-N-{2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5yl)oxylethyl}acetamide;
- N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1,1-dimethylethyl}-2-hydroxyacetamide;
- 2-hydroxy-N-{(2R)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy]propyl}acetamide;
- 2-hydroxy-N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino} quinazolin-5-yl)oxy[propyl]acetamide;
- N-((2R)-2-{[4-(4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)quinazolin-5-yl]oxy}propyl)-2hvdroxyacetamide:
- 2-hydroxy-*N*-{(2*R*)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino} quinazolin-5-vl)oxylpropyl}acetamide;
- N-{(2R)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5yl)oxylpropyl}acetamide;
- N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxylpropyl}acetamide;
- N-((2R)-2-{[4-({4-[(3-fluorobenzyl)oxy]-3-methylphenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy[propyl]acetamide;

- 2-hydroxy-N-methyl-N-{(2R)-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxy]propyl}acetamide;
- 2-hydroxy-N-methyl-N-{(2R)-2-[(4-{[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl|amino}quinazolin-5-yl)oxy|propyl}acetamide;
- 2-hydroxy-N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(5-methylisoxazol-3vl)methoxylphenyl}amino)quinazolin-5-vlloxylpropyl)acetamide:
- N-methyl-N-{(1R)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyl] amino}quinazolin-5-yl)oxylethyl}acetamide;
- N-methyl-N-{(1R)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}acetamide;
- N-{(1R)-2-[(4-{[3-chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]-1-methylethyl}-2-hydroxy-N-methylacetamide;
- 2-hydroxy-N-methyl-N-{(1R)-1-methyl-2-[(4-{[3-methyl-4-(pyridin-2-ylmethoxy)phenyllamino}quinazolin-5-yl)oxy]ethyl}acetamide;
- 2-hydroxy-N-methyl-N-{(1R)-1-methyl-2-[(4-{[3-methyl-4-(1,3-thiazol-4ylmethoxy)phenyllamino}quinazolin-5-yl)xxylethyl}acetamide;
- N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-1hydroxy-N-methylcyclopropanecarboxamide;
- (2S)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5yl)oxylpropyl}-2-hydroxy-N-methylpropanamide:
- N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}-2hvdroxy-N.2-dimethylpropanamide:
- (2R)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy|propyl}-2-hydroxy-N-methylpropanamide;
- (2R)-N-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy[propyl}-2-methoxy-N-methylpropanamide;

- $2-hydroxy-N-methyl-N-((2R)-2-\{[4-(\{3-methyl-4-[(6-methylpyridin-3-methyl-4-[(6-methyl-4-[(6-methyl-4$
 - vl)oxylphenyl}amino)quinazolin-5-ylloxy}propyl)acetamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- - yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)glycinamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl}-2-pyrrolidin-1-ylacetamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)-2-morpholin-4-ylacetamide;
- N-methyl-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-ylloxy}propyl)-2-(4-methylpiperazin-1-yl)acetamide;
- 2-hydroxy-*N*-methyl-*N*-((2S)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}propyl)acetamide;
- N-methyl-N-((2S)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-ylloxylpropyl)acetamide:
- N-methyl-N-((2S)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-ylloxy}propyl)-2-pyrrolidin-1-ylacetamide;
- (2S)-2,4-dihydroxy-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxylphenyl}amino)quinazolin-5-ylloxylpropyl)butanamide:
- (2S)-4-bromo-2-hydroxy-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxylphenyl}amino)quinazolin-5-ylloxylpropyl)butanamide;
- N-(2-chloroethyl)-N-((2R)-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy]propyl)urea;
- 2-hydroxy-N-methyl-N-((1R)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;
- N-methyl-N-((1R)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;

yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;

N-methyl-N-((1S)-1-methyl-2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;

methyl-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5yl)oxy]ethyl}methylcarbamate;

N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N,N-dimethylurea;

N-(2-chloroethyl)-N-{2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-methylurea;

 $N-\{(2R)-2-[(4-\{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}$ quinazolin-5-yl)oxy]propyl}-N-methylurea;

[((R)-2-{4-[3-chloro-4-(pyridin-2-ylmethoxy)phenylamino]quinazolin-5yloxy}propylcarbamoyl)methyl]methylcarbamic acid tert-butyl ester;

N¹-{(2R)-2-[(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}quinazolin-5-yl)oxy]propyl}N²-methylglycinamide;

2-hydroxy-N-methyl-N-(2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5-yl]oxy}ethyl)acetamide;

N-methyl-N-(2-{[4-({3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl}amino)quinazolin-5vlloxy}ethylacetamide: and

N-{2-[(4-{[3-chloro-4-(1-methyl-1-pyridin-2-ylethoxy)phenyl]amino}quinazolin-5-yl)oxy]ethyl}-N-methylacetamide;

or a pharmaceutically acceptable salt thereof.

Claim 19 (previously presented): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 or claim 18 in association with a pharmaceutically-acceptable diluent or carrier.

Claims 20-23 (cancelled).

Claim 24 (currently amended): A process for the preparing a quinazoline derivative of formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

a) coupling, optionally in the presence of a suitable base, a quinazoline of formula II:

$$R^{6} R^{2} R^{4aQ}$$
 $R^{2} N$
 $(R^{3})_{n}$
 $(R^{1})_{m}$

wherein R¹, R², R³, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, X¹, Q¹, m, and n have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a carboxylic acid of formula III, or a reactive derivative thereof:

A-COOH

ш

wherein A has any of the meanings defined in claim 1 except that any functional group is optionally protected; or

(b) for the preparation of the compounds of the formula I wherein X¹ is OC(R⁻)₂, SC(R⁻)₂ or N(R⁻)C(R⁻)₂, reacting, optionally in the presence of a suitable base, a quinazoline of formula IV:

of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of the formula V or a salt thereof:

$$Q^1$$
- $C(R^7)_2$ - L^1

wherein L¹ is a suitable displaceable group and Q¹ and R⁷ have any of the meanings defined in claim 1 except that any functional group is optionally protected; or

(c) for the preparation of the compounds of the formula I wherein A is R¹⁴ and R¹⁴ is NHR¹⁷ or Q3-X5- (wherein R17 and Q3 are as defined in claim 1 and X5 is NH), the coupling of a quinazoline of the formula II as defined above in (a) with an isocyanate of formula IIIa:

A-NCO

Ша

wherein A is R¹⁴ as previously defined in this section except that any functional group is optionally protected; or

reacting a quinazoline of the formula II wherein R⁶ is hydrogen: (d)

wherein R^1 , R^2 , R^3 , R^4 , R^{4a} , R^5 , R^{5a} , X^1 , Q^1 , m, and n have any of the meanings defined in claim 1 except that any functional group is optionally protected, with α -hydroxy- γ -butyrolactone wherein any functional group is optionally protected; or

(e) coupling of a quinazoline of formula VI:

wherein R^1 , R^4 , R^5 , R^5 , R^6 , R^6 , A and m have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of formula IIb:

$$R^2$$
 N
 X^1-Q^1

wherein R², R³, X¹, Q¹ and n have any of the meanings defined in claim 1 except that any functional group is optionally protected; or

(f) for the preparation of the compounds of the formula I wherein X¹ is O and Q¹ is 2-pyridyl, 4-pyridyl, 2-pyrimidyl, 4-pyrimidyl, 2-pyrazinyl or 3-pyridazinyl, reacting, optionally in the presence of a suitable base and a suitable catalyst, of a quinazoline of the formula VII:

VII

wherein R¹, R², R³, R⁴, R^{4a}, R⁵, R^{5a}, R⁶, A, m and n have any of the meanings defined in claim 1 except that any functional group is optionally protected, with 2-bromopyridine, 4-bromopyridine, 2-chloropyrimidine, 4-chloropyrimidine, 2-chloropyridine; or 3-chloropyridazine; or

(g) for the preparation of the compounds of the formula I wherein A is Z-(CR¹²R¹³)_p-, wherein Z is NR¹⁶R¹⁷, the reaction, optionally in the presence of a suitable base, of a quinazoline of the formula VIII:

$$L^{1} - (CR^{12}R^{13})_{p} \cap (R^{5}R^{4} \cap (R^{3})_{n})_{n}$$

VIII

wherein L^1 is a suitable displaceable group and R^1 , R^2 , R^3 , R^4 , R^5 , R^5 a, R^6 , R^{12} , R^{13} , X^1 , Q^1 , m, n and p have any of the meanings defined in claim 1 except that any functional group is optionally protected, with a compound of formula **IXa**, or a reactive derivative thereof:

H-NR 16R 17

137 -

wherein R¹⁶ and R¹⁷ have any of the meanings defined in claim 1 except that any functional group is optionally protected;

and thereafter, optionally:

- (i) converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I:
- (ii)(i) removing any protecting group that is present;
- (iii)(ii) forming a pharmaceutically acceptable salt.

Claim 25 (previously presented): A method for treating a breast tumour in a warm-blooded animal in need of such treatment, which comprises administering to the animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, according to claim 1.

Claims 26-30 (cancelled).